UBS Analyst Event: Fireside Chat With Medincell Management - September 18, 2024
2024年9月17日 - 12:45AM
ビジネスワイヤ(英語)
Regulatory News:
Christophe Douat, CEO, and Richard Malamut, CMO, will
participate in a fireside chat to present Medincell's (Paris:MEDCL)
portfolio and R&D pipeline key development with UBS analysts on
18 September at 11:00am ET.
Investors can access the presentation remotely, either live
or on replay, following this link: Registration | Investor
Call with Medincell Mgmt (open-exchange.net)
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical
licensing company developing long-acting injectable drugs in many
therapeutic areas. Our innovative treatments aim to guarantee
compliance with medical prescriptions, to improve the effectiveness
and accessibility of medicines, and to reduce their environmental
footprint. They combine active pharmaceutical ingredients with our
proprietary BEPO® technology which controls the delivery of a drug
at a therapeutic level for several days, weeks or months from the
subcutaneous or local injection of a simple deposit of a few
millimeters, entirely bioresorbable. The first treatment based on
BEPO® technology, intended for the treatment of schizophrenia, was
approved by the FDA in April 2023, and is now distributed in the
United States by Teva under the name UZEDY® (BEPO® technology is
licensed to Teva under the name SteadyTeq™). We collaborate with
leading pharmaceutical companies and foundations to improve global
health through new treatment options. Based in Montpellier,
Medincell currently employs more than 140 people representing more
than 25 different nationalities. UZEDY® and SteadyTeq™ are
registered trademarks of Teva Pharmaceuticals.
www.medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240916974970/en/
David Heuzé - Head of Corporate and Financial Communications,
and ESG david.heuze@medincell.com / +33 (0)6 83 25 21 86
Grace Kim - Head of US Financial Strategy and IR
grace.kim@medincell.com / +1 (646) 991-4023
Investors Relations France Louis-Victor
Delouvrier/Alban Dufumier medincell@newcap.eu / +33 (0)1 44 71
94 94
Media Relations Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94
Medincell (EU:MEDCL)
過去 株価チャート
から 9 2024 まで 10 2024
Medincell (EU:MEDCL)
過去 株価チャート
から 10 2023 まで 10 2024